A longitudinal study reports that serial plasma cell-free DNA measurements can predict glioblastoma progression risk during treatment. Investigators tracked a volumetric cfDNA index and found it correlated with radiological progression over time. The approach focuses on monitoring dynamics rather than single time-point biomarkers, which may help clinicians anticipate progression while therapy is ongoing. For glioblastoma, where imaging and clinical trajectories can lag behind molecular changes, the ability to forecast risk could support more timely treatment decisions. The findings add to the growing evidence base for cfDNA as a practical tool for treatment monitoring, though broader validation across cohorts and platforms will be required.